$5.51
0.18% yesterday
Nasdaq, Sep 26, 10:00 pm CET
ISIN
US45773H2013
Symbol
INO

Inovio Pharmaceuticals, Inc. Stock price

$5.51
-1.99 26.53% 1M
-6.87 55.49% 6M
-0.61 9.97% YTD
+1.00 22.09% 1Y
-87.73 94.09% 3Y
-19.57 78.03% 5Y
-115.69 95.45% 10Y
Nasdaq, Closing price Thu, Sep 26 2024
-0.01 0.18%
ISIN
US45773H2013
Symbol
INO
Sector

Key metrics

Market capitalization $143.06m
Enterprise Value $45.62m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 77.32
P/S ratio (TTM) P/S ratio 242.47
P/B ratio (TTM) P/B ratio 1.48
Revenue growth (TTM) Revenue growth -93.85%
Revenue (TTM) Revenue $590.00k
EBIT (operating result TTM) EBIT $-117.12m
Free Cash Flow (TTM) Free Cash Flow $-112.84m
Cash position $110.42m
EPS (TTM) EPS $-5.11
P/E forward negative
P/S forward 428.11
EV/Sales forward 136.52
Short interest 11.64%
Show more

Is Inovio Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Inovio Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Inovio Pharmaceuticals, Inc. forecast:

3x Buy
50%
3x Hold
50%

Analyst Opinions

6 Analysts have issued a Inovio Pharmaceuticals, Inc. forecast:

Buy
50%
Hold
50%

Financial data from Inovio Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
0.59 0.59
94% 94%
100%
- Direct Costs 2.80 2.80
44% 44%
475%
-2.20 -2.20
148% 148%
-373%
- Selling and Administrative Expenses 35 35
18% 18%
5,992%
- Research and Development Expense 77 77
41% 41%
13,010%
-114 -114
32% 32%
-19,376%
- Depreciation and Amortization 2.80 2.80
44% 44%
475%
EBIT (Operating Income) EBIT -117 -117
32% 32%
-19,850%
Net Profit -122 -122
28% 28%
-20,617%

In millions USD.

Don't miss a Thing! We will send you all news about Inovio Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Inovio Pharmaceuticals, Inc. Stock News

Neutral
PRNewsWire
10 days ago
PLYMOUTH MEETING, Pa. , Sept. 17, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will present at the following scientific conference: World Congress of Electroporation Oral Presentation by Trevor Smith, VP...
Neutral
Seeking Alpha
about 2 months ago
Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Thomas Hong - Manager of Investor Relations Jacqueline Shea - President & Chief Executive Officer Steve Egge - Chief Commercial Officer Michael Sumner - Chief Medical Officer Peter Kies - Chief Financial Officer Conference Call Participants Anish Nikhanj - RBC Capital Marke...
Neutral
PRNewsWire
about 2 months ago
PLYMOUTH MEETING, Pa. , Aug. 8, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the second quarter of 2024 and provided an update on recent company developments.
More Inovio Pharmaceuticals, Inc. News

Company Profile

Inovio Pharmaceuticals, Inc. is a late-stage biotechnology company. It engages in the discovery, development, and commercialization of DNA-based immunotherapies and vaccines. The firm's drug candidates include SynCon immunotherapies which helps break the immune system's tolerance of cancerous cells; and CELLECTRA delivery system which facilitates optimized cellular uptake of the SynCon immunotherapies. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

Head office United States
CEO Jacqueline Shea
Employees 122
Founded 1983
Website www.inovio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today